Edward Dyson

Ed counsels public and emerging private companies, entrepreneurs, investors and investment banks on a wide range of capital markets and corporate finance transactions.

• Engagements

  IPOs / Direct Listings / Follow-ons:

  • AccuStem Sciences Inc. on its Main Market demerger and US OTC listing
  • Ananda Pharma plc on its US OTCQB listing
  • Attica Bank S.A. on Athens Stock Exchange follow-ons
  • Autolus Therapeutics plc on its Nasdaq IPO 
  • B&M European Value Retail S.A. (B&M Stores) on its Main Market IPO
  • capAI plc on Main Market stock loan arrangements
  • Castillo Copper Limited on ASX / Main Market follow-ons
  • Cobra Resources plc on Main Market follow-ons 
  • Codex Acquisitions plc on its Main Market SPAC IPO 
  • Dispensa Group (formerly Zamaz) plc on its Main Market direct listing and PIPE
  • Endava plc on its NYSE IPO
  • e-Therapeutics plc on its US OTCQX listing
  • Farmacosmo S.p.A. on its Euronext Growth Milan IPO
  • GEM (formerly URA) Resources plc on its Main Market IPO
  • Hamak Gold Limited on its Main Market IPO 
  • Heptares Therapeutics Limited (as shareholder) on the Nasdaq IPO of Centessa Pharmaceuticals plc
  • Hummingbird Ventures Limited (as shareholder) on the Main Market IPO of Deliveroo plc
  • Kistos Holdings plc on its AIM direct listing 
  • Mercantile Ports & Logistics Limited on AIM follow-ons 
  • National World plc on its Main Market SPAC IPO 
  • Nightstar Therapeutics plc on its Nasdaq IPO
  • OKYO Pharma Limited on its Main Market IPO, Nasdaq dual-listing, Main Market de-listing and global follow-ons
  • One Media IP Group plc on AIM follow-ons
  • Panther Metals plc on Main Market follow-ons
  • Realm Therapeutics plc on its direct dual-listing on Nasdaq and subsequent AIM delisting
  • RegTech Open Project plc on its Main Market direct listing
  • Renalytix plc on its demerger, AIM IPO and Nasdaq dual-listing
  • "Romgaz" S.A. on its Main Market (GDR) IPO
  • Scancell Holdings plc on various AIM follow-ons
  • Supply@ME Capital plc on Main Market follow-ons
  • TCS Group Holdings plc on its Main Market (GDR) IPO
  • Tiziana Life Sciences Limited on its AIM to Main Market listing step-up, Nasdaq dual-listing, Main Market de-listing and Bermudan re-domiciliation 
  • the banks on a Main Market follow-on by Nuformix plc
  • the banks on a Main Market convertible loan note financing by Hawkwing plc
  • the banks on the Main Market IPOs of Exova Group plc and Glencore plc
  • the banks on the Main Market direct listing of Metro Bank plc
  • the banks on the Nasdaq IPOs and follow-ons of Bicycle Therapeutics plc, Compass Pathways plc, (aborted) Horizon Discovery plc, (aborted) Kymab Limited, (aborted) Mereo BioPharma Group plc, NuCana plc and (aborted) Verona Pharma plc
  • VEF AB on its First North to Nasdaq Stockholm Main Market listing step-up

  Public / Private M&A:

  • Kistos plc on its possible offer for Serica Energy plc
  • Kistos Holdings plc on its acquisition of Mime Petroleum A.S.
  • Mindflair (formerly Pires Investments) plc on its proposed takeover by Tern plc
  • MightyHive Inc. on its acquisition by S4 Capital plc
  • National World plc on its possible offer for Reach plc
  • National World plc on its recommended cash acquisition by Media Concierge (Holdings) Limited
  • National World plc on the auction of The Telegraph Media Group
  • Nxera Pharma (formerly Sosei) on its acquisition of Idorsia’s Japan and APAC (ex-China) pharmaceuticals business
  • Realm Therapeutics plc on its Nasdaq recommended takeover by Essa Pharma Inc.

  De-SPACs / Reverse Takeovers:

  • Atlas Metals Group plc on its (aborted) Main Market reverse takeover of Compagnie Minière de Oumejrane
  • Kinnevik AB on the NYSE de-SPAC of Babylon Health with Alkuri Global Acquisition Corp.
  • Kistos plc on its AIM reverse takeover of Tulip
  • National World plc on its Main Market reverse takeover of JPI Media
  • RockRose Energy plc on its Main Market reverse takeovers of certain North Sea interests acquired from Marathon Oil UK and Idemitsu Petroleum
  • Shard Credit Partners Limited (as shareholder) on the AIM reverse takeover by Location Sciences Group plc of Sorted Holdings Limited
  • Technologies New Energy plc on its Main Market de-SPAC of Technologies New Energy S.A.
  • Tooru plc on its AIM reverse takeover of certain operating subsidiaries of S-Venture plc
  • VNV Global AB on the Nasdaq de-SPACs of Swvl with Queen's Gambit Growth Capital and Gett with Rosecliff Acquisition Corp I

  Private Capital:

  • A financial investor on a Seed financing round for a UK fintech
  • A tech business on its Series A financing
  • FOMTECH Limited (Floww) on its Series B and C financings
  • Metro Africa Xpress Inc. on its Series B financing

  Strategic Advisory:

  • Floww on its strategic partnership with London Stock Exchange Group to create a global private capital market
  • Force Over Mass Capital LLP on partnership matters
  • Nxera Pharma on its collaboration and licensing agreements with Neurocrine Biosciences Inc., Eli Lilly and Co., Viatris and another global biomedical company
  • Round Group Limited on the establishment of its Apex influencer and creator business

  Please note: Ed's experience includes that prior to joining Orrick.